SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Safe Disposal of 
Opioids Act of 2019’’. 
SEC. 2. GRANTS FOR DISPOSAL SITES FOR UNWANTED PRE-
SCRIPTION MEDICATIONS. 
Section 203 of the Comprehensive Addiction and Re-
covery Act of 2016 (21 U.S.C. 822a) is amended by add-
ing at the end the following: 
‘‘(c) GRANTS FOR DISPOSAL SITES FOR UNWANTED 
PRESCRIPTION MEDICATIONS.— 
‘‘(1) GRANTS.— 
‘‘(A) AWARDS.—In carrying out subsection 
(b), the Attorney General shall award grants to 
covered entities to establish or maintain dis-
posal sites for unwanted prescription medica-
tions. 
‘‘(B) LIMITATION.—Of the total amount of 
awards under subparagraph (A) for a fiscal 
year, the Attorney General shall not award 
more than 10 percent to covered entities that 
are— 
‘‘(i) State, local, or tribal law enforce-
ment agencies; or 
‘‘(ii) manufacturers, distributors, or 
reverse distributors of prescription medica-
tions. 
VerDate Sep 11 2014 
01:03 Jun 13, 2019
Jkt 089200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H3171.IH
H3171
kjohnson on DSK79L0C42 with BILLS
‘‘(2) DISCOUNTS FOR ELIGIBLE PATIENTS.— 
‘‘(A) IN
GENERAL.—The Secretary of 
Health and Human Services shall establish a 
mechanism by which amounts paid by an eligi-
ble patient for an active opioid are discounted 
at time of payment or purchase to ensure that 
such patient does not pay any amount attrib-
utable to a fee under paragraph (3), with as lit-
tle burden on the patient as possible. 
‘‘(B) DEFINITION.—For purposes of sub-
paragraph (A), the term ‘eligible patient’ 
means— 
‘‘(i) a patient for whom any active 
opioid (as so defined) is prescribed to treat 
pain relating to cancer or cancer treat-
ment; 
‘‘(ii) a patient participating in hospice 
care; and 
‘‘(iii) in the case of the death or inca-
pacity of a patient described in subpara-
graph (A) or (B) or any similar situation 
as determined by the Secretary of Health 
and Human Services, the appropriate fam-
ily member, medical proxy, or similar rep-
resentative or the estate of such patient. 
VerDate Sep 11 2014 
01:03 Jun 13, 2019
Jkt 089200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H3171.IH
H3171
kjohnson on DSK79L0C42 with BILLS
‘‘(3) FEES.— 
‘‘(A) IN GENERAL.—There is hereby im-
posed on the sale of any active opioid by the 
manufacturer, producer, or importer a fee equal 
to 1 cent per 100 milligrams so sold. 
‘‘(B) SPECIAL RULES.— 
‘‘(i) DEFINITION.—In this paragraph, 
the term ‘active opioid’— 
‘‘(I) means any controlled sub-
stance (as defined in section 102 of 
the Controlled Substances Act, as in 
effect on the date of the Safe Disposal 
of Opioids Act of 2019) which is 
opium, an opiate, or any derivative 
thereof; and 
‘‘(II) excludes any prescribed 
drug which is used exclusively for the 
treatment of opioid addiction as part 
of a medically assisted treatment ef-
fort. 
‘‘(ii) EXCLUSION OF OTHER INGREDI-
ENTS.—In the case of a product that in-
cludes an active opioid and another ingre-
dient, subparagraph (A) shall apply only to 
VerDate Sep 11 2014 
01:03 Jun 13, 2019
Jkt 089200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H3171.IH
H3171
kjohnson on DSK79L0C42 with BILLS
the portion of such product that is an ac-
tive opioid. 
‘‘(4) AUTHORIZATION
OF
APPROPRIATIONS.— 
For fiscal year 2020 and each subsequent fiscal 
year, there is authorized to be appropriated to carry 
out this subsection an amount not to exceed the ag-
gregate amount of the fees collected pursuant to 
paragraph (3).’’. 
Æ 
VerDate Sep 11 2014 
01:03 Jun 13, 2019
Jkt 089200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6301
E:\BILLS\H3171.IH
H3171
kjohnson on DSK79L0C42 with BILLS